Traduction de «costs and a higher » (Néerlandais → Français) :

Net income rose 1% to USD 2.1 billion as the 13% increase in Group operating income was largely offset by a loss from associated companies due to USD 189 million of charges for Roche’s restructuring of Genentech and an Alcon-related R&D project impairment, increased financing costs and a higher tax rate.
Le résultat net a augmenté de 1% à USD 2,1 milliards, car la hausse de 13% du résultat opérationnel du Groupe a été largement contrebalancée par une perte provenant des sociétés associées en raison de charges d’USD 189 millions pour la restructuration de Genentech par Roche et d’une perte de valeur pour un projet de R&D lié à Alcon, d’un accroissement des coûts de financement et du taux d’imposition.

The core operating income margin of 33.3% of net sales was affected by lower Other Revenues and sales to other divisions (–0.7 percentage points) as well as higher Cost of Goods Sold (–1.0 percentage points) as a result of lower fixed overhead absorption and a devaluation of inventories to reflect lower standard costs, in addition to higher royalties.
La marge opérationnelle core de 33,3% du chiffre d’affaires net a été réduite par une baisse des autres produits et des ventes à d’autres divisions (-0,7 point de pourcentage) et par une hausse des coûts des ventes (-1,0 point de pourcentage) induite par la réduction de l’absorption des frais fixes et une dévaluation des stocks pour refléter un tassement des coûts standards en plus d’une hausse des redevances.

There were lower sales to other divisions (-0.4 percentage points), higher Other revenues (+0.1 percentage points) and higher Cost of Goods Sold (-1.1 percentage points).
Il y a eu une baisse des ventes aux autres divisions (-0,4 points), une hausse des Autres produits (+0,1 point) et du Coût des ventes (-1,1 point).

Net income, however, fell 8% to USD 6.1 billion from the impact of Alcon-related financing costs as well as significantly reduced income from investments in Roche and Alcon in the third quarter of 2009 and a higher tax rate.
Le résultat net a cependant diminué de 8% à USD 6,1 milliards, sous l’impact des coûts de financement liés à Alcon ainsi que de la baisse importante du résultat provenant des investissements dans Roche et Alcon au troisième trimestre 2009 et d’une hausse du taux d’imposition.

Cost of Goods Sold improved 0.5 percentage points driven by productivity gains partly offset by higher royalties.
Le Coût des ventes s’est amélioré de 0,5 point en raison de gains de productivité en partie compensés par une hausse des redevances.

Other revenues decreased 0.1 percentage points and Cost of Goods Sold increased 0.4 percentage points, mainly driven by higher royalties.
Autres revenus ont diminué de 0,1 point, tandis que le Coût des ventes a augmenté de 0,4 point, essentiellement sous l’influence d’une hausse des redevances.

Cost of Goods Sold (-0.7 percentage points) was impacted by lower fixed overhead absorption, in addition to higher Lucentis royalties.
Le coût des ventes (-0,7 point de pourcentage) a été impacté par une baisse de l’absorption des frais fixes et par une augmentation des redevances de Lucentis.

Unit cost: €2.53 Costs of interventions in current practice based on Dutch empirical data Cost calculations of interventions in increased implementation program based on Dutch practice guidelines and (for the duration of NRT and bupropion) on international trials (Cochrane meta-analysis) Costs of smoking-related diseases were taken into account, estimates based on Dutch cost-ofillness study that allocated total direct health care costs to diseases.
Unit cost: €2.53 Costs of interventions in current practice based on Dutch empirical data Cost calculations of interventions in increased implementation program based on Dutch practice guidelines and (for the duration of NRT and Buproprion) on international trials (Cochrane meta-analysis) Costs of smoking-related diseases were taken into account, estimates based on Dutch cost-ofillness study that allocated total direct health care costs to diseases.

Estimated cost of bupropion is similar to the estimated cost of NRT GP advice can be opportunistic, i.e. given during a consultation primarily concerned with another health matter.
Estimated cost of Buproprion is similar to the estimated cost of NRT GP advice can be opportunistic, i.e. given during a consultation primarily concerned with another health matter.

MeSH: Radiotherapy; Cost and Cost Analysis
MeSH : Radiotherapy; Cost and Cost Analysis.